echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Tapinarof cream successfully achieved phase III clinical treatment of psoriasis

    NEJM: Tapinarof cream successfully achieved phase III clinical treatment of psoriasis

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Psoriasis is a chronic, immune- mediated skin disease that affects approximately 2% of the world’s population
    .


    At present, a variety of systemic targeted and biological therapies have been used for the treatment of moderate to severe psoriasis in adults.


    Researchers of


    Patients with mild to severe plaque psoriasis participated in the study, including 2 parallel studies
    .


    The patient’s baseline PGA score is 2 (mild) to 4 (severe, the PGA score ranges from 0 to 4, the higher the score, the more severe the psoriasis symptoms), the patient’s affected skin area accounts for 3% to 20% of the total surface.


    Quality of Life

    In trial 1 and trial 2, 692 and 674 patients were screened respectively , of which 510 and 515 patients were included in the study
    .


    In trial 1, 35.


    In screening test 1, 35.


    PGA response rate increased significantly after Tapinarof treatment

    PGA response rate increased significantly after Tapinarof treatment

    Studies believe that once a day topical treatment with 1% Tapinarof cream can significantly alleviate the symptoms of patients with plaque psoriasis
    .

    Local treatment with 1% Tapinarof cream once a day can significantly alleviate the symptoms of patients with plaque psoriasis
    .


    Local treatment with 1% Tapinarof cream once a day can significantly alleviate the symptoms of patients with plaque psoriasis


    Original source:

    Mark G.


    Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.